Shelter Pharma (543963) Q4 22/23 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 22/23 earnings summary
23 Oct, 2026Executive summary
FY23 revenue from operations reached ₹361.5m vs ₹300.6m; net profit rose to ₹52.1m from ₹18.6m.
Pharmaceutical manufacturing remained the core activity; an IPO of up to ₹350m was approved, with draft prospectus approval received June 30, 2023.
Financial highlights
Revenue from operations was ₹361.5m vs ₹300.6m; total income was ₹361.6m vs ₹300.6m.
Profit before tax was ₹69.8m vs ₹27.5m; net profit was ₹52.1m vs ₹18.6m.
Total expenses rose to ₹282.0m from ₹273.1m; raw material consumed was ₹263.1m vs ₹267.5m.
Other expenses included ₹3.0m of bad debts written off; the reserves note also records a ₹9.0m write-off against bad advances.
Outlook and guidance
No dividend was recommended, with profits retained to support future expansion.
IPO proceeds of up to ₹350m were planned for a proposed BSE SME listing; draft prospectus approval was received June 30, 2023.
Latest events from Shelter Pharma
- Revenue and net profit rose in FY18; profits were retained and no dividend recommended.543963
Q4 17/18 - Revenue declined, but FY19 net profit and EPS improved; no dividend was recommended.543963Q4 18/19
- Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY22 revenue and profit rose sharply, while COVID disruptions remained a sales risk.543963Q4 21/22
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25
- Revenue and net profit rose year-over-year, with robust financials and new auditor appointments.543963Q4 24/25